Development of a Cloud Platform for Advanced Diagnostics Based on Clinical and Omics Data.

Patients with clinical and genetic findings consistent with a monogenic SAID belonging to one of the following categories: inflammasomopathies, unfolded protein response (UPR) and cellular stress disorders, type I interferonopathies, actinopathies, NF-κB hyperactivation disorders, or DADA2. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

Patients with clinical manifestations consistent with PFAPA, SURF (as defined in Papa R et al., 2020), chronic recurrent multifocal osteomyelitis (CRMO)/SAPHO syndrome, or systemic juvenile idiopathic arthritis (sJIA). Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

Patients with clinical manifestations consistent with a SAID, after excluding defined monogenic or multifactorial/complex autoinflammatory diseases based on clinical and/or genetic findings. Physician Global Assessment (PGA) \> 2 on a 0-10 visual analogue scale (VAS) and elevated C-reactive protein (CRP) levels.

Widespread pain with symptoms persisting for at least 3 months. Patients meeting the clinical criteria defined in Wolfe et al. (2016).